Hypoglycemia can present differently from person to person and therefore an individualized approach is imperative to manage each patient’s symptoms and risk factors. With the increasing number of treatment and management options becoming available, deciding on the best course of action can be more difficult.
This interactive CME-accredited webcast aims to support you to make these decisions.
Watch experts in a lively debate presenting real-life patient cases, and discussing where newer therapies can be best utilized.
This program is suitable for, but not limited to, endocrinologists, diabetologists, and primary care practitioners.
Professor of Clinical Diabetes, University of Sheffield, Sheffield, UK
Simon Heller is Professor of Clinical Diabetes at the University of Sheffield, and Director of Research and Development and Honorary Consultant Physician at Sheffield Teaching Hospitals Foundation Trust.
He trained in clinical diabetes at Queen’s Medical Centre, Nottingham and in research at the University of Nottingham and Washington University, St Louis, USA. He was Editor of Diabetic Medicine from 2000-2005. He is currently the National Speciality Lead in Diabetes to the NIHR Clinical Research Network and an NIHR Senior Investigator. He is a former member of Diabetes UK Science and Research Advisory Group, a member of the UK NIHR Programme Grants for Applied Research Panel and chairs the UK Juvenile Diabetes Research Foundation, UK Scientific Advisory Committee.
He chairs the International Hypoglycaemia Study group, an independently funded group of international experts with research and clinical expertise in hypoglycaemia. The group has a remit to reduce the burden of hypoglycemia though educational activities.
He chaired the glucose control group of the ADVANCE trial, is a steering committee member of the EXAMINE trial and was the PI on the REPOSE trial measuring the effectiveness of insulin pumps.
His research interests include the pathophysiological responses to hypoglycemia and hypoglycemia unawareness, the potential contribution and mechanisms of hypoglycemia to cardiovascular mortality, the use of insulin analogues and other technologies to reduce hypoglycemia. He also conducts research concerned with developing programs (including the DAFNE intervention) to encourage more effective diabetes self-management. He has authored over 200 original research articles and reviews.
Advisory Board Member: Eli Lilly, Novo Nordisk, Sanofi Aventis, Takeda, Zealand Pharma, UN-EEG, Boehringer Ingelheim. Consultant: Eli Lilly, Novo Nordisk. Speaker’s Bureau: Eli Lilly, Novo Nordisk.
Professor of Primary Care Diabetes and Vascular Medicine, University of Leicester, Leicester, UK
Kamlesh Khunti is Professor of Primary Care Diabetes and Vascular Medicine at the University of Leicester, UK. He is Co-Director of the Leicester Diabetes Centre and leads a research group that is currently working on the early identification of, and interventions with, people who have diabetes or are at increased risk of developing diabetes. His work has influenced national and international guidelines on the screening and management of people with diabetes. Professor Khunti is also Director of the UK National Institute for Health Research (NIHR) Collaboration for Leadership in Applied Health Research and Care East Midlands and Director of The Real World Evidence Unit. He is a NIHR Senior Investigator and Principal Investigator on several major national and international studies. He has published over 650 articles.
Professor Khunti is a Fellow of the Academy of Medical Sciences and is currently an advisor to the Department of Health, a Clinical Advisor for the National Institute for Health and Care Excellence (NICE) and Secretary of the Primary Care Study Group of the European Association for the Study of Diabetes. He is Past Chair of the Department of Health–RCGP Committee on Classification of Diabetes and is Past Chair of the NICE Guidelines on Prevention of Diabetes. In addition, he is Co-Director of the Diabetes MSc at Leicester University. He has won numerous awards nationally and internationally.
Grants/Research Support: AstraZeneca, Novartis, Novo Nordisk, Sanofi-Aventis, Lilly, Pfizer, Boehringer Ingelheim and Merck Sharp & Dohme.
Hermelinda C Pedrosa
Medical Doctor and Scientific Coordinator Research Centre, Endocrinology Unit, Regional Taguatinga Hospital, Secretariat of Health, Brasilia, Brazil
Hermelinda C. Pedrosa is an endocrinologist who graduated at the Federal University of Paraiba State; Residency in Internal Medicine and Specialization in Endocrinology at the Hospital de Base de Brasilia. She also trained in Oxford (UK) under a scholarship from the National Council of Research (CNPq) for a two-year fellowship.
She has served as President of the Diabetes Department of the Brazilian Endocrinology and Metabolism (SBEM, 2019-2020); President of the Brazilian Diabetes Society (SBD, 2018-2019).
Dr Pedrosa has focused her career in teaching at the Medicine Course and Residency Programme; serving as Chair of the Diabetes Education Programme in Brasília (1997-2012) when she implemented many pioneer treatment facilities, which included the short- and long-acting insulin analogues dispensing program in 2004 and 2005, which led to a broad free-access program to other states in Brazil; the first free delivery of CIIS in the SUS (Brazilian public health service) which was implemented under her coordination (2008).
Dr Pedrosa has written chapters in national and international books, contributed to various papers and national studies.
Currently, she works as head of the Research Centre of the Endocrinology Unit at the Regional Hospital of Taguatinga (DF); is member of the D-FOOT Advisory Board for SACA; Advisor of Government Relations for the SBD. She has been Principal Investigator for Fiocruz in Biomanguinhos, Rio de Janeiro, since 2018, which is a most respected institution of research in Brazil.
Hermalinda Pedrosa declares financial or non-financial support from Fiocruz – Biomanguinhos Rio de Janeiro, Urgo Medical, Masters Specialty Pharma, Servier do Brasil, AstraZeneca, Novo Nordisk, Roche.
Elizabeth R Seaquist
Pennock Family Chair in Diabetes Research and Professor of Medicine, University of Minnesota, MN, USA
Elizabeth Seaquist is the Director of the Division of Diabetes, Endocrinology and Metabolism and holds the Pennock Family Chair in Diabetes Research at the University of Minnesota. She is also the Vice Chair for Clinical Affairs in the Department of Medicine and the Associate Dean for Medical Specialties and Primary Care for the Medical School.
As a clinical investigator, Dr Seaquist is interested in hypoglycemia and the complications of diabetes. Her research focuses on the effect of diabetes on brain metabolism, structure, and function. She directs the University of Minnesota sites for the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE) study and the Researching Cardiovascular Events with a Weekly Incretin in Diabetes (REWIND) study.
Dr Seaquist was the site investigator for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. She served as the President of Medicine and Science of the American Diabetes Association in 2014. She has an active clinical practice and is board certified in Internal Medicine and Endocrinology, Diabetes, and Metabolism.
Elizabeth Seaquist declares financial or nonfinancial support from NIH, JDRF, American Board of Internal Medicine.
In support of improving patient care, this activity has been planned and implemented by North American Center for Continuing Medical Education (NACCME) and Springer Healthcare IME. NACCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
This program has been made possible with an educational grant from Novo Nordisk A/S.
Email: IME@springer.com Address: Springer Healthcare IME The Campus, 4 Crinan Street London, N1 9XW, UK